Added to YB: 2025-12-17
Pitch date: 2025-12-14
ADVM [neutral]
Adverum Biotechnologies, Inc.
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Market Cap
$96.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.88
P/E
-0.51
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
Weird Events, Part 2: Some quick hits $ADVM
ADVM (quick overview): CEO/COO bought ~178k shares (almost 1% of co) in final 2 trading days before Lilly merger closed at $3.56+CVR. Insiders also granted 500k+ PSUs in Sept to vest post-merger, disclosed only after deal closed. Unusual timing suggests CVR worth significantly more than $1.72 risk-adjusted value.
Read full article (3 min)